Xiang Yu
Member of Yanfeng Hu's gastric-cancer lab who contributed to a study showing how a microbiota-linked metabolite, kynurenic acid, drives resistance to PD-1 blockade
Nanfang Hospital, Southern Medical University · Gastric-cancer immunology & microbiome
Xiang Yu is based in Yanfeng Hu's lab at Nanfang Hospital, a group focused on how the gastric tumor microenvironment and its resident microbiota shape immunotherapy response. He co-authored the 2026 study tracing how microbiota-associated kynurenic acid drives resistance to PD-1 blockade through an ITGA2-mTOR-CTSV signaling axis in gastric cancer.
He is first author on a related 2026 Cell Reports Medicine paper from the same lab on bacterial extracellular vesicles enhancing anti-PD-1 efficacy via macrophage FPR1 signaling, and a co-author on other 2024-2025 papers from the same Guangdong Provincial Key Laboratory for GI-tumor precision medicine.
Milestones in the Atlas
| Year | Evidence | Study |
|---|---|---|
| 2026 | A | Microbiota-associated kynurenic acid drives PD-1 blockade resistance through an ITGA2-mTOR-CTSV axis in gastric cancer. REN2026 Co-author on the study identifying microbiota-derived kynurenic acid as a driver of anti-PD-1 resistance via an ITGA2-mTOR-CTSV axis in gastric cancer. |
Co-authors in the Atlas
People with a profile here who share at least one study with Xiang Yu.
- Jiaqiang Jiang Member of the Nanfang Hospital gastric-cancer surgery team that traced how a tumor-enriched gut bacterium rewires CD8+ T cells through an mTOR-linked checkpoint to blunt anti-PD-1 therapy.